Pipeline — registered trials by phase
No registered trials in this stage.
A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)
— · Duchenne Muscular Dystrophy · Completed · est. 2014-05
Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet
— · Muscular Dystrophy, Duchenne · Completed · est. 2015-08
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
— · Clostridium Difficile Infection · Completed · est. 2016-08
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
— · Clostridium Difficile Infection · Completed · est. 2015-10
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
— · Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) · Recruiting · est. 2030-10-31
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
— · Non-Small Cell Lung Cancer · Recruiting · est. 2028-04
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
— · Clostridioides Difficile Infection · Completed · est. 2021-11-17
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
— · Metastatic Colorectal Cancer (CRC) · Recruiting · est. 2028-05-31
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
— · Non-Small Cell Lung Cancer · Active Not Recruiting · est. 2028-12-31
Phase III Study of AK112 for NSCLC Patients
— · Non-Squamous Non-small Cell Lung Cancer · Active Not Recruiting · est. 2025-04-12
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Summit Therapeutics is lead sponsor; 10 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- PRE 14A2026-10-06PRE 14A
- 8-K2026-09-29Current report (material event)
- 8-K2026-09-15Current report (material event)
- 8-K2026-09-14Current report (material event)
- 8-K2026-09-03Current report (material event)
- 8-K2026-08-26Current report (material event)
- 8-K2026-08-05Current report (material event)
- 8-K2026-07-23Current report (material event)
- 424B52026-07-23Prospectus (offering)
- 10-Q2026-07-23Quarterly report
- 8-K2026-07-23Current report (material event)
- 8-K2026-07-22Current report (material event)
- 8-K2026-06-12Current report (material event)
- 8-K2026-06-11Current report (material event)
- 424B52026-06-10Prospectus (offering)
- S-3ASR2026-06-09S-3ASR
- 8-K2026-06-03Current report (material event)
- 8-K2026-06-01Current report (material event)
- 10-Q2026-04-30Quarterly report
- 8-K2026-04-30Current report (material event)
- DEFA14A2026-04-17DEFA14A
- ARS2026-04-17Annual report to holders
- DEF 14A2026-04-17Proxy statement
- PRE 14A2026-04-06PRE 14A
- S-82026-02-23Employee stock plan
- 10-K2026-02-23Annual report
- 8-K2026-02-23Current report (material event)
- 8-K2026-01-29Current report (material event)
- 8-K2026-01-12Current report (material event)
- 8-K2025-11-07Current report (material event)
- S-3ASR2025-10-29S-3ASR
- 8-K2025-10-22Current report (material event)
- 10-Q2025-10-20Quarterly report
- 8-K2025-10-20Current report (material event)
- 8-K2025-09-08Current report (material event)
- 8-K2025-08-11Current report (material event)
- 8-K2025-08-11Current report (material event)
- 424B52025-08-11Prospectus (offering)
- 10-Q2025-08-11Quarterly report
- 8-K2025-06-20Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.